SINOMAB BIO-B (03681) announced its interim results for 2025, reporting other income and gains of RMB 9.802 million, representing a year-on-year increase of 126.95%, while research and development costs reached RMB 32.74 million. The company disclosed that during the reporting period, its two core drug pipelines, Suciraslimab (SM03) and SM17, both achieved breakthrough progress.
The group's flagship product, Suciraslimab, is the world's first-in-class monoclonal antibody (mAb) targeting the CD22 receptor. Recently, Suciraslimab demonstrated breakthrough results in preclinical in vivo studies for treating systemic lupus erythematosus (SLE). With its unique advantages of "regulating autoimmune networks through B cell interactions plus organ damage protection benefits," Suciraslimab not only significantly reduces anti-double-stranded DNA (anti-dsDNA) antibody levels but also shows superior performance compared to existing drugs in improving lupus nephritis (LN) proteinuria and renal pathological damage.
In the first half of 2025, China's innovation drug license-out transaction volume reached $66 billion, up 36% year-on-year and approximately 27.2% higher than the full-year 2024 total of $51.9 billion. Over 50% of licensing projects involved preclinical or Phase I clinical trials, reflecting international pharmaceutical companies' recognition of China's early-stage innovation.
Additionally, China's National Medical Products Administration has compressed innovative drug clinical trial approval time from 14 months to 30 days, while the National Healthcare Security Administration's "Sixteen Measures for Innovative Drugs" supports payment-side expansion, promoting the recovery of China's innovative drug market. The central government's "new quality productive forces" strategy also provides a favorable environment for the group's innovative R&D.
As the first Hong Kong-based Chapter 18A biopharmaceutical company, the group will continue to focus on innovation as its core competitive advantage, driving the commercialization of existing drug pipelines and the development of new drug pipelines. The group believes that Suciraslimab and SM17 will further validate their best-in-class characteristics in subsequent clinical trials, addressing unmet medical needs for SLE and AD patients.